Clinical Trials

10 results for Prostate Cancer

UTSW SBRT Prospective Clinical Registry for Oligometastic Disease, Consolidation Therapy, Debulking Prior to Chemotherapy, or Re-Irradiation

  • Condition: Cancer Patients Receiving Stereotactic Body RTX
  • Intervention: Radiation: SBRT
  • Study ID: NCT02170181
View Trial

Observational Study of Immune Responses in Prostate Cancer Patients Following Stereotactic Body Radiotherapy (SBRT)

  • Condition: Oligometastatic Prostate Cancer
  • Study ID: NCT01777802
View Trial

The Role of Stereotactic Body Radiotherapy in the Management of Castration-Resistant Prostate Cancer With Oligometastases: An Adaptive Phase II/III Randomized Trial.

  • Condition: Castration-resistant Prostate Cancer Patients With Oligometastases
  • Intervention: Drug: Leuprolide Acetate, Drug: Goserelin Acetate, Drug: Triptorelin, Drug: Enzalutamide, Radiation: Stereotactic Body Radiation Therapy
  • Study ID: NCT02685397
View Trial

A Randomized Phase II Trial of Stereotactic Body Radiation Therapy (SBRT) With or Without Durvalumab (MEDI4736) in Oligometastatic Recurrent Hormone Sensitive Prostate Cancer Patients

  • Condition: Node; Prostate, Bone Metastases, Prostate Cancer Patients
  • Intervention: Combination Product: SBRT + Durvalumab, Radiation: SBRT
  • Study ID: NCT03795207
View Trial

A Phase II Randomized Trial of RAdium-223 and SABR Versus SABR for oligomEtastatic Prostate caNcerS (RAVENS)

  • Condition: Prostate Cancer
  • Intervention: Drug: Radium-223, Radiation: stereotactic ablative radiotherapy (SABR)
  • Study ID: NCT04037358
View Trial

A Randomized Phase III Trial of Local Ablative Therapy For Hormone Sensitive Oligometastatic Prostate Cancer [PLATON]

  • Condition: Prostate Cancer Metastatic
  • Intervention: Radiation: Ablative Radiation Therapy, Other: Standard of care
  • Study ID: NCT03784755
View Trial

A Randomized, Phase II Study of Apalutamide +/- Stereotactic Body Radiotherapy (SBRT) in Castration-Resistant Prostate Cancer Patients With Oligometastatic Disease on PSMA-PET Imaging

  • Condition: Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, PSA Progression, Stage IV Prostate Adenocarcinoma AJCC v7
  • Intervention: Drug: Apalutamide, Radiation: Stereotactic Body Radiation Therapy
  • Study ID: NCT03503344
View Trial

Oligomet-DK. National Danish Protocol. Surgery+ SBRT for M1 Prostate Cancer Patients

  • Condition: Prostate Cancer Metastatic
  • Intervention: Procedure: RARP, Radiation: SBRT, Drug: ADT
  • Study ID: NCT04086290
View Trial

Fluciclovine (FACBC) PET/CT Site-Directed Therapy of Oligometastatic Prostate Cancer (Flu-BLAST-PC)

  • Condition: Prostate Adenocarcinoma, PSA Level Greater Than or Equal to 0.5, PSA Level Less Than Ten
  • Study ID: NCT04175431
View Trial

Androgen Deprivation Therapy for Oligo-recurrent Prostate Cancer in Addition to radioTherapy

  • Condition: Prostate Cancer
  • Study ID: NCT04302454
View Trial